AT4 Antibody

What is the AT4 receptor and how does it relate to IRAP?

The angiotensin IV receptor (AT4 receptor) is now recognized as insulin-regulated aminopeptidase (IRAP, EC 3.4.11.3), a membrane-spanning enzyme belonging to the M1 family of zinc-dependent metallo-peptidases . Angiotensin IV (Ang IV), which exerts profound effects on memory and learning, binds to this receptor . Research has demonstrated that AT4 receptor ligands, including Ang IV and structurally unrelated compounds like LVV-hemorphin-7, function as potent inhibitors of IRAP catalytic activity . The physiological effects of AT4 ligands are believed to result, in part, from inhibition of IRAP cleavage of neuropeptides involved in memory processing .

How are AT4/IRAP antibodies validated for research applications?

Validation of AT4/IRAP antibodies requires multiple complementary approaches:

• Western blot verification: Validated antibodies should detect specific bands at expected molecular weights—approximately 165 kDa for full-length membrane IRAP (mIRAP) and 150 kDa for soluble IRAP (sIRAP) .

• Knockout controls: The specificity of antibodies can be confirmed by the absence of bands in protein lysates from IRAP knockout models. For example, research demonstrated that novel anti-IRAP antibodies showed no binding in cardiac tissue from IRAP knockout mice while successfully detecting IRAP isoforms ranging from ~120-165 kDa in wildtype mice .

• Cross-reactivity assessment: Antibodies should be tested against related aminopeptidases to ensure specificity.

• Multiple epitope targeting: Using antibodies that recognize different domains of IRAP provides stronger validation, particularly when developing sandwich assays that require distinct binding sites .

What are the challenges in developing highly specific AT4/IRAP antibodies?

Researchers face several significant challenges when developing AT4/IRAP antibodies:

• Soluble vs. membrane-bound forms: IRAP exists in both membrane-bound and soluble secreted forms. Most commercially available anti-IRAP antibodies target the cytoplasmic N-terminal domain rather than the soluble C-terminal domain, limiting detection of the secreted form .

• Limited specificity: Concerns have been raised about the low specificity and high variability between lots of commercially available antibodies for angiotensin receptors . This problem extends to AT4/IRAP antibodies and makes reproducibility difficult across studies.

• Dimerization complexities: IRAP has a demonstrated propensity to form homodimers, creating additional complexity for antibody targeting and binding .

• Conformational changes: In plasma samples, IRAP may adopt different conformations or interact with binding proteins, requiring specific sample preparation to expose antibody binding sites .

How can researchers optimize antibody selection for different AT4/IRAP detection applications?

Optimization varies by application and target form:

• For soluble IRAP detection: Select antibodies specifically targeting the C-terminal domain. In one study, researchers developed four distinct monoclonal antibodies (RF7, RB9, RH3, RG4) with high specificity for the soluble C-terminal domain .

• For sandwich ELISA applications: Test multiple antibody combinations, as some pairs may bind to epitopes in similar regions and fail to work together. For example, the RF7-RB9-B and RF7-RG4-B combinations successfully detected sIRAP, while RF7-RH3 and RB9-RG4 combinations consistently failed .

• For Western blot applications: Consider antibodies that recognize both native and denatured forms of the protein. The novel antibodies RF7, RB9, RH3, and RG4 all successfully bound to both mIRAP and sIRAP in Western blots with specific bands at ~150-160 kDa .

• For immunohistochemistry: Consider antibody formats optimized for tissue penetration and epitope access in fixed tissues.

What are emerging non-antibody-based methods for AT4/IRAP detection?

Recent advances offer alternative approaches for AT4/IRAP quantification:

• Mass spectrometry-based assays: Researchers have developed "the first non-antibody-based sensitive and specific targeted quantitative mass spectrometry assay for angiotensin receptors" . These approaches may overcome the specificity limitations of antibody-based methods.

• Nanobody technology: Although not specifically developed for AT4/IRAP, engineered nanobodies have shown promise for targeting other angiotensin receptors. For instance, nanobody antagonists have been developed for the AT1R receptor with tunable pharmacokinetics . Similar approaches could potentially be applied to AT4/IRAP.

What are the best practices for developing a sandwich ELISA using AT4/IRAP antibodies?

Developing a sensitive and specific sandwich ELISA for AT4/IRAP requires careful optimization:

Researchers have successfully developed sandwich ELISAs with the following performance characteristics:

The sensitivity (lower limit of detection) was calculated using twelve replicates of zero standards in each experiment .

How do storage and handling conditions affect AT4/IRAP antibody performance?

While specific data for AT4/IRAP antibodies is limited, general principles of antibody storage apply:

• Temperature effects: Inappropriate storage temperatures can significantly alter binding affinity. A study with trastuzumab showed that storage temperature affects the apparent KI values .

• Freeze-thaw cycles: Repeated freeze-thaw cycles can compromise antibody structure and function. Studies investigating "the effect of short-term exposure to organic solvents, as well as freezing temperature and repeated freeze/thaw cycles" showed these conditions can reduce binding affinity .

• Buffer composition: The choice of buffer can influence antibody stability and performance.

• Biotinylation effects: Chemical modifications like biotinylation may impact binding ability. For example, with IRAP antibodies, "biotinylated antibodies which were detected using either an anti-mouse HRP secondary antibody or streptavidin-HRP, had varying decreases in their binding ability compared to their untagged counterparts" .

What criteria should be used to evaluate newly developed AT4/IRAP antibodies?

Comprehensive evaluation should include:

• Binding specificity: Verify target recognition using both positive controls (e.g., purified recombinant protein, cells/tissues known to express IRAP) and negative controls (e.g., IRAP knockout tissues) .

• Cross-reactivity assessment: Test against structurally similar proteins, particularly other aminopeptidases.

• Epitope mapping: Determine which domain of IRAP the antibody recognizes to understand its applications (e.g., detection of membrane vs. soluble forms).

• Performance across applications: Evaluate in multiple techniques (Western blot, immunohistochemistry, ELISA) to determine versatility.

• Batch-to-batch consistency: Assess variability between production lots, which is particularly important for polyclonal antibodies .

• Titration experiments: Determine optimal working concentrations across applications. "A titration experiment is done by first selecting a fixed incubation time and then a series of experimental dilutions of the antibody. Each dilution should be tested on the same sample type to keep the same experimental conditions" .

How are AT4/IRAP antibodies being used in biomarker research?

AT4/IRAP is emerging as a potential biomarker for various conditions:

• Cardio-metabolic diseases: "There is growing interest in the use of the enzyme, insulin regulated aminopeptidase (IRAP), as a biomarker for conditions such as cardio-metabolic diseases and ischemic stroke, with upregulation in its tissue expression in these conditions" .

• Pregnancy monitoring: Research has demonstrated "significant increases in the levels of sIRAP in plasma from women at the later stages of pregnancy" with "a consistent level of expression around 3 µg/ml detected in term samples" .

• Neurodegenerative conditions: Given IRAP's role in memory processing, researchers are investigating its potential as a biomarker in neurodegenerative diseases.

What approaches are being used to improve AT4/IRAP antibody developability?

Recent advances in antibody engineering applicable to AT4/IRAP antibodies include:

• Deep learning models: Researchers have developed "deep learning-based design and experimental validation" approaches for antibodies, which could potentially be applied to generate improved AT4/IRAP antibodies .

• Fc engineering: For therapeutic applications, modifications to the Fc region can tune pharmacokinetics. For example, "to extend circulating half-life, we fused AT118 to an IgG1 Fc, dimerizing the nanobody and raising the molecule's molecular weight above the ~70 kDa renal filtration cutoff" .

• Disulfide cyclization: Research on AT4 receptor ligands has shown that "disulfide cyclizations of angiotensin IV can deliver ligands with high IRAP/AT4 receptor affinity" . Similar structural constraints could potentially be applied to improve antibody binding.

• Humanization processes: For therapeutic applications, antibodies need to be humanized to reduce immunogenicity while maintaining binding affinity .